A randomized phase I study of two different schedules of BAY 43-9006 [sorafenib] in patients with acute myeloid leukemia or myelodysplastic syndrome

Trial Profile

A randomized phase I study of two different schedules of BAY 43-9006 [sorafenib] in patients with acute myeloid leukemia or myelodysplastic syndrome

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2010

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Feb 2010 Results published in Leukemia and Lymphoma.
    • 10 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top